Valuation: AbbVie Inc.

Market Cap 431B 374B 350B 320B 605B 41,051B 613B 4,097B 1,608B 20,511B 1,618B 1,583B 68,268B P/E 2026 *
32.1x
P/E 2027 * 23.1x
Enterprise Value 494B 428B 401B 367B 693B 47,011B 702B 4,692B 1,841B 23,488B 1,853B 1,813B 78,179B EV / Sales 2026 *
7.3x
EV / Sales 2027 * 6.59x
Free-Float
95.71%
Yield 2026 *
2.84%
Yield 2027 * 2.96%
1 day-0.95%
1 week-5.26%
Current month-2.82%
1 month-4.27%
3 months+18.94%
6 months+9.15%
Current year+6.73%
1 week 241.2
Extreme 241.2
256.2
1 month 241.2
Extreme 241.2
267.47
Current year 190.75
Extreme 190.75
267.47
1 year 190.75
Extreme 190.75
267.47
3 years 135.85
Extreme 135.85
267.47
5 years 105.56
Extreme 105.56
267.47
10 years 55.06
Extreme 55.0623
267.47
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

62 0.0000%
30/06/26 Free

Director

134 0.0000%
08/05/26 Free

Director

1,118 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%-5.26%+24.23%+65.08% 435B
+1.89%+3.20%+59.70%+165.18% 1,043B
-0.24%+0.45%+50.64%+52.02% 621B
0.00%+3.20%+46.70%+37.60% 361B
+0.58%-1.26%+35.52%+40.54% 293B
-1.55%-9.78%+5.61%+8.62% 251B
-0.73%+4.44%+42.22%+66.41% 220B
-0.24%-13.15%-4.02%-44.69% 201B
-0.68%-0.32%+18.66%+66.32% 164B
+1.51%+5.18%+9.49%-25.19% 147B
Average -0.35%-2.13%+28.88%+43.19% 373.62B
Weighted average by Cap. -0.48%-1.26%+39.04%+73.15%

Financials

2026 *2027 *
Net sales 67.62B 58.68B 54.95B 50.27B 94.89B 6,442B 96.13B 643B 252B 3,218B 254B 248B 10,712B 73.7B 63.96B 59.89B 54.78B 103B 7,020B 105B 701B 275B 3,508B 277B 271B 11,675B
Net income 13.96B 12.12B 11.35B 10.38B 19.59B 1,330B 19.85B 133B 52.09B 665B 52.42B 51.29B 2,212B 19.02B 16.51B 15.46B 14.14B 26.7B 1,812B 27.04B 181B 70.97B 905B 71.43B 69.88B 3,014B
Net Debt 62.56B 54.29B 50.84B 46.5B 87.79B 5,960B 88.94B 595B 233B 2,978B 235B 230B 9,911B 55.04B 47.76B 44.72B 40.91B 77.23B 5,243B 78.24B 523B 205B 2,619B 207B 202B 8,718B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
06/08/26 $243.87 -0.95% 4,569,928
05/08/26 $246.20 +0.98% 5,193,732
04/08/26 $243.80 -0.53% 8,028,831
03/08/26 $245.10 -2.33% 7,435,935
31/07/26 $250.94 -2.51% 7,258,176
Trader
Investor
Global
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
243.87USD
Average target price
273.39USD
Spread / Average Target
+12.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock